Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2024-01-10 00:00:00 ET · period of report 2024-01-09 · accession 0000950170-24-003648 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-10 | 2024-01-09 | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale | $4.37 | -14.4K | 371.2K | -4% | -$62.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-09 | S | D | 14,391 | $4.37 | 371,248 | D | — | — | (F2) Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. |